ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences
May 11 2016 - 8:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company
developing targeted cancer therapeutics using its proprietary
antibody-drug conjugate (ADC) technology, today announced that the
following presentations by Company management at upcoming investor
conferences will be webcast:
- UBS Global Healthcare
Conference9:00 am ET, May 25, 2016
- Jefferies 2016 Healthcare
Conference10:00 am ET, June 9, 2016
The webcasts will be accessible live through the “Investors”
section of the Company’s website, www.immunogen.com; a replay will
be available at the same location for approximately a week.
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted anticancer therapeutics using its proprietary ADC
technology. The Company’s lead product candidate, mirvetuximab
soravtansine, has demonstrated encouraging activity and
tolerability in early clinical testing for folate receptor
α-positive ovarian cancer and is progressing to advanced clinical
testing. ImmunoGen's ADC technology is used in Roche's marketed
product, Kadcyla®, and in programs in development by partners
Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
More information about the Company can be found at
www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160511005165/en/
ImmunoGen, Inc.Carol Hausner, 781-895-0600info@immunogen.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024